罗沙司他联合多糖铁复合物对慢性肾脏病合并肾性贫血患者贫血状态及铁代谢相关指标的影响

Effect of Rosastat Combined with Polysaccharide Iron Complex on Anemia Status and Iron Metabolism Related Indexes in Patients with Chronic Kidney Disease and Renal Anemia

目的:探讨罗沙司他联合多糖铁复合物对慢性肾脏病(CKD)合并肾性贫血患者贫血状态及血清转铁蛋白(TRF)、血清铁蛋白(SF)及转铁蛋白饱和度(TSAT)的影响。方法:选取2020年8月-2021年8月肇庆市第一人民医院收治的82例CKD合并肾性贫血患者,按随机数字表法将其分为对照组(41例)和观察组(41例)。对照组给予重组人促红素(rHuEPO)联合多糖铁复合物治疗,观察组给予罗沙司他联合多糖铁复合物治疗,两组患者均持续治疗8周。比较两组治疗前后贫血指标、铁代谢指标、脂代谢指标水平及治疗期间的不良反应发生情况。结果:与治疗前比较,治疗后两组患者的血浆红细胞计数(RBC)、血红蛋白(Hb)及红细胞压积(Hct)及血清TRF、SF、TSAT水平均升高,且观察组均高于对照组;与治疗前比较,治疗后两组患者血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)水平均下降,且观察组均低于对照组(P<0.05)。观察组不良反应发生率为9.76%,低于对照组的34.15%,差异有统计学意义(P<0.05)。两组治疗后血清高密度脂蛋白胆固醇(HDL-C)水平比较,差异无统计学意义(P>0.05)。两组治疗后血清高密度脂蛋白胆固醇(HDL-C)水平与治疗前比较,差异均无统计学意义(P>0.05)。结论:罗沙司他可有效纠正CKD合并肾性贫血患者的贫血状态,改善机体铁代谢和脂代谢,且安全性较高。

Objective:To investigate the effect of Rosastat combined with Polysaccharide Iron Complex on anemia status and serum transferrin(TRF),serum ferritin(SF)and transferrin saturation(TSAT)in chronic kidney disease(CKD)patients complicated with renal anemia.Method:A total of 82 CKD patients with renal anemia who were admitted to First People's Hospital of Zhaoqing City from August 2020 to August 2021 were selected,they were divided into the control group(41 cases)and the observation group(41 cases)according to the random number table method.The control group was treated with Recombinant Human Erythropoietin(rHuEPO)combined with Polysaccharide Iron Complex,and the observation group was treated with Rosastat combined with Polysaccharide Iron Complex,both groups were treated for 8 weeks.The levels of anemia indexes,iron metabolism indexes,lipid metabolism indexes and the occurrence of adverse reactions during treatment were compared between the two groups before and after treatment.Result:Compared with those before treatment,the plasma red blood cell count(RBC),hemoglobin(Hb),hematocrit(Hct)and serum TRF,SF,TSAT levels of the both groups of patients increased after treatment,those of the observation group were higher than those of the control group;compared with those before treatment,serum total cholesterol(TC)and low-density lipoprotein cholesterol(LDL-C)levels of the both groups decreased after treatment,those of the observation group were lower than those of the control group(P<0.05).The incidence of adverse reactions of the observation group was 9.76%,which was lower than 34.15%of the control group,the difference was statistically significant(P<0.05).There was no significant difference in serum high density lipoprotein cholesterol(HDL-C)level between the two groups after treatment(P>0.05).There were no significant differences in serum high density lipoprotein cholesterol(HDL-C)between the two groups after treatment and before treatment(P>0.05).Conclusion:Rosastat can effectively correct anemia in CKD patients with renal anemia,improve iron metabolism and lipid metabolism,and has high safety.